Loading...
  • acute
  • A complete blood cell (CBC) count with differential demonstrates anemia and thrombocytopenia to varying degrees in individuals with acute lymphoblastic leukemia (ALL). (medscape.com)
  • Chest radiographs may reveal signs of pneumonia and/or a prominent mediastinal mass in some cases of T-cell acute lymphoblastic leukemia (ALL). (medscape.com)
  • I. Determine the response rate of bortezomib in combination with a chemotherapy backbone of doxorubicin (doxorubicin hydrochloride), vincristine (vincristine sulfate), PEG-asparaginase (pegaspargase), and dexamethasone in patients with relapsed/refractory acute lymphoblastic leukemia. (clinicaltrials.gov)
  • V. Determine whether bortezomib induces reactive oxygen species (ROS) in circulating acute lymphoblastic leukemia (ALL) blast cells. (clinicaltrials.gov)
  • DLT will be defined as a grade III or greater toxicity developing within 3 weeks of the T cell infusion, as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4 or new development of grade II-IV acute GVHD within 3 weeks of the T cell infusion that requires treatment with systemic glucocorticosteroids. (clinicaltrials.gov)
  • Patients will also be monitored for secondary or immune-mediated graft rejection and or onset of grade II-IV acute GVHD following the administration of WT1-specific T-cell infusions. (clinicaltrials.gov)
  • Determine the incidence of acute graft-versus-host disease (GVHD), and nonrelapse mortality (within 100 days after transplantation) in these patients. (knowcancer.com)
  • Correlate donor-versus-recipient natural killer cell alloreactivity with graft rejection/failure, acute GVHD, and relapse of malignant disease in patients treated with this regimen. (knowcancer.com)
  • Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. (vita34.sk)
  • und Ribera, J.-M.: Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. (vita34.sk)
  • Cochran, M.: Complex Case Study: Four Stem Cell Transplants for Acute Myeloid Leukemia (AML). (vita34.sk)
  • hematologic
  • Because patients may still have transplantation associated cytopenia or may have residual disease that may be associated with cytopenias, hematologic toxicity will be excluded in assessing DLT. (clinicaltrials.gov)
  • However, in autologous transplantation for solid tumor in which hematologic recovery is rapid and immune suppression is less severe than allogeneic transplantation, there is no standard guideline for the use of prophylactic antibiotics whereas infection is the most important cause of morbidity. (clinicaltrials.gov)
  • Cyclophosphamide when added to tacrolimus and mycophenolate mofetil is safe and effective in preventing severe graft-versus-host disease (GVHD) in most patients with hematologic malignancies undergoing transplantation of bone marrow from half-matched (haploidentical) donors. (clinicaltrials.gov)
  • survival
  • A clinical study that involved 510 patients and compared four different chemotherapy combinations has revealed that anticancer responses and duration of survival were the same for all four treatments. (cancerconnect.com)
  • mortality
  • To reduce the chance of infection and therefore, to reduce the morbidity and mortality from severe infection, various prophylactic antibiotics including antibacterial, antifungal, and antiviral agents have been used according to standard guideline in allogeneic stem cell transplantation. (clinicaltrials.gov)
  • eligible
  • Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. (clinicaltrials.gov)
  • decitabine
  • We performed quantitative real-time PCR in marrow mononuclear cells to examine the expression of hENT1 , hENT2 , DCK , and CDA prior to therapy in 98 MDS patients initially treated with decitabine. (biomedcentral.com)
  • HENT1 knockdown was performed by shRNA in the SKM-1 cell line, and the effect of this on the demethylation ability of decitabine on long interspersed nucleotide element 1 (LINE1) was investigated. (biomedcentral.com)
  • Knockdown of hENT1 in SKM-1 cells weakened the demethylation effect on LINE1 induced by decitabine. (biomedcentral.com)
  • Because the biochemical targets of decitabine are intracellular, the mandatory first step in the production of cytotoxicity is permeation across the cell membrane. (biomedcentral.com)
  • Decitabine and physiologic nucleosides are hydrophilic, and diffusion through the cell membrane lipid layer is slow. (biomedcentral.com)
  • When transporting into the cell, decitabine is phosphorylated into monophosphorylated derivative 5-azadCMPby deoxycytidine (DCK). (biomedcentral.com)